PLANTATION, Fla., Nov. 1 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that its wholly owned subsidiary, ViraGenics,
Inc., has renewed its agreement with the Roslin Institute (Scotland) to
continue their collaboration to develop and commercialize avian transgenic
technology as a biomanufacturing platform for the efficient and economical
production of protein-based drugs.
"We are very pleased to continue this exciting collaboration with Roslin,
and this new agreement focuses on very specific objectives of significant
importance over the next 12 months," stated Viragen's President and CEO, Mr.
Charles A. Rice. "Due to the pioneering nature of this platform, our initial
work has been necessarily broad in evaluating various technologies for our
purpose. As we have progressed, we have made important technological advances
resulting in a focus towards final-stage development activities on specific
product candidates."
Mr. Rice confirmed, "We have previously reported historic achievements
including germline transmission and tissue-targeted drug expression, which are
prerequisites for the design of a commercially viable system. Evaluation
studies are now ongoing for two 'blockbuster' candidates that are commercially
marketed by leading companies. We would expect a stream of milestones being
achieved for avian-expressed versions of these product candidates as studies
progress, demonstrating the distinct advantages offered."
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
